Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer
January 3rd 2024Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.
Read More